Engflag

Vyepti

Quick links to important sections

Vyepti

Vyepti_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vyepti

Quick Facts

Property Description
Active ingredient Eptinezumab-jjmr (Eptinezumab)
Form Solution for intravenous infusion
Pharmacological class Calcitonin Gene-Related Peptide (CGRP) Antagonist
Common use Preventive treatment of migraine in adults
Origin Biological product (Humanized IgG1 monoclonal antibody)

Vyepti: A Targeted Biological Product for Migraine

Vyepti is a prescription medicine intended for the preventive treatment of migraine in adults. Its active component, Eptinezumab-jjmr (Eptinezumab), is a biological product—specifically, a humanized IgG1 monoclonal antibody—that is distinctively formulated as an aqueous solution for intravenous infusion in a single-dose vial. This unique delivery method ensures immediate and complete systemic availability of the medication upon administration, a key differentiating factor compared to other CGRP antagonist injections. The medicine is manufactured by Lundbeck and is one of the few migraine preventatives delivered via a controlled infusion.

What Type of Medicine is Vyepti?

Vyepti is firmly categorized within the therapeutic class of Calcitonin Gene-Related Peptide (CGRP) Antagonists. This classification is based on the drug's mechanism of directly binding to the CGRP ligand, a protein in the nervous system that is highly active during a migraine attack. By neutralizing the CGRP signal, the drug prevents it from binding to its receptor, thereby blocking the pathway believed to cause the migraine pain. This highly selective action is clinically recognized for providing targeted, high-precision therapeutic potential for migraine prevention.

General Purpose: Preventing Migraine Attacks

The primary purpose of Vyepti is to offer sustained, proactive preventive therapy for patients experiencing frequent episodic migraine or chronic migraine. This means the medicine is designed to reduce the overall number of migraine days, rather than being used to treat an acute attack once symptoms have begun. The long-acting nature of the Eptinezumab antibody allows it to provide consistent migraine control over a sustained period, contributing to a substantial reduction in the patient's migraine burden.

Regulatory References

  1. NIH Bookshelf

What side effects are possible with Vyepti?

Possible side effects and safety information

The safety profile for Vyepti (eptinezumab-jjmr) is organized by official regulatory documents based on the frequency and type of adverse reactions observed in clinical trials and postmarketing reports.

Adverse Reactions Classified by Frequency

Adverse reactions classified as Common (may affect up to 1 in 10 people) include Nasopharyngitis (symptoms of a common cold) and Fatigue [EMA SmPC]. Additionally, certain Hypersensitivity reactions, such as pruritus (itching), flushing (redness), and rash, are also officially classified as common [FDA Labeling].

Serious Adverse Reactions

The most clinically significant adverse reactions defined in regulatory safety documents are Serious Hypersensitivity Reactions, which have included Anaphylaxis and Angioedema [FDA Labeling]. These serious events are noted to occur most commonly during or immediately following the intravenous infusion [EMA SmPC]. The medicine is strictly Contraindicated in any patient with a known history of serious hypersensitivity to eptinezumab-jjmr or any of its excipients.

Population and Vascular Safety Notes

The official labeling includes safety notes regarding special populations. For pregnancy, use is advised to be avoided as a precautionary measure because human IgG antibodies are known to cross the placental barrier. For breast-feeding, no specific data is available, but the potential for excretion of human IgG in breast milk is noted [EMA SmPC]. Postmarketing reports have also included high-level safety notes concerning the potential for new-onset or worsening of Hypertension and Raynaud's phenomenon within the Vascular disorders system [U.S. Prescribing Information].

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding Vyepti (eptinezumab) overdose is primarily based on supportive care and the management of known adverse reactions, as a specific clinical overdose syndrome has not been defined.

In clinical studies, the highest dose of Vyepti administered was 1,000 mg (significantly higher than the routine dose) without the occurrence of clinically significant adverse reactions or tolerability issues. Regulatory documents state that there is no known specific antidote for eptinezumab overdose.

Management and Emergency Actions

If an overdose occurs, treatment should consist of general supportive measures and be symptomatic, as clinically indicated. Given the serious nature of infusion-related events, the prescribing information emphasizes recognizing life-threatening reactions:

Situation Required Action (as per Regulatory Labeling)
Overdose Treat symptomatically and institute general supportive measures.
Serious Hypersensitivity Discontinue infusion immediately and initiate appropriate therapy.

Patients must seek emergency medical help right away if they experience any signs of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat, trouble breathing, hives, or a rash.

Therapeutic Uses of Vyepti

What Vyepti Treats: Main Uses and Benefits

Vyepti is generally used in areas where additional symptomatic support is needed for the prevention of migraine in adults. This means the medicine is applied in conditions involving recurrent or episodic manifestations to reduce the recurrence of episodes. The focus is on proactive, long-term symptom management.

It is commonly used for managing prevention in adults with both episodic migraine and chronic migraine. This application is relevant in clinical settings marked by conditions associated with acute or disruptive episodes, including for patients who require additional symptomatic support beyond initial management strategies.

“The goal is to support patients during difficult episodes by easing distress and helping to maintain a sense of stability when symptoms are more noticeable.”

The primary therapeutic benefit plays a role in managing a reduction in the frequency of symptoms related to physical discomfort, which helps address symptom clusters that may become intense or disruptive. The medication may assist with reducing the need for acute rescue medications and contributes to improved comfort during symptomatic periods.

Quick Fact: Therapeutic Focus: Migraine Symptom Management

Property Description
Primary Goal Supports the reduction of recurrent migraine episodes.
Target Conditions Episodic migraine and chronic migraine.
Core Benefit Contributes to easing the overall symptom load related to physical discomfort.
Use Scenario Commonly used when symptoms intensify and supportive relief is needed.

Regulatory References

  1. European Medicines Agency overview on Vyepti

Eligibility and Restrictions for Use

Eligibility Scope

Vyepti is officially indicated for the preventive treatment of migraine in adults. Regulatory guidelines strictly define which populations are eligible or excluded from using this medicine.

Category Official Regulatory Status
Populations for whom use is allowed Adults for the prevention of migraine.
Populations for whom use is contraindicated Patients with known serious hypersensitivity to eptinezumab-jjmr or any of its excipients. Reactions have included anaphylaxis and angioedema.
Age-related eligibility rules Use is not established in the pediatric population (under 18 years of age). There is no relevant use in children below 6 years. Use in older adults (ge65 years) has limited data, but no dose adjustment is required.
Condition-specific eligibility rules No dose adjustment is required for patients with renal impairment or hepatic impairment. Use is restricted for patients with Hereditary Fructose Intolerance (HFI) due to the presence of sorbitol.
Pregnancy and lactation eligibility Pregnancy: Limited data; use should be avoided as a precautionary measure. Lactation: Data are not available on presence in human milk, and a risk cannot be excluded during the first few days after birth.

Eligibility-Context Constraints

The most severe restriction is the absolute contraindication for patients with serious hypersensitivity. The medicine's use is formally limited to the adult population, and due to a lack of safety data from clinical studies, special consideration is required for patients with a history of cardiovascular disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Vyepti

The official interaction profile for Vyepti (Eptinezumab-jjmr) is largely defined by the drug's biological structure, which minimizes the risk of systemic drug-drug interactions.

Interaction Scope

Property Official Regulatory Statement
Medicinal product categories with documented interactions None are explicitly listed as altering Vyepti's systemic exposure.
Mechanistic basis of interactions Eptinezumab is not metabolized by Cytochrome P450 (CYP) enzymes; therefore, interactions with CYP substrates, inhibitors, or inducers are considered unlikely.
Timing-based interaction rules No other medications must be administered through the same intravenous infusion set or mixed with eptinezumab.
Population-specific interaction notes No specific alteration to the interaction profile is expected in patients with hepatic or renal impairment.

Interaction Classifications (High-Level)

Classification Official Regulatory Statement
Interaction severity classification Systemic pharmacokinetic interactions with co-administered drugs are deemed unlikely. The combination is formally contraindicated in patients with hereditary fructose intolerance (HFI) or serious hypersensitivity.
Interaction-context constraints The drug's intravenous administration imposes a compatibility restriction for all other intravenous agents.

Resulting Interaction Structure

Official interaction statements:

  • The systemic pharmacokinetic interaction risk is low because the medication is not metabolized by the major CYP450 enzyme system.
  • A procedural restriction requires that no other medicines be mixed with eptinezumab or administered through the same infusion line.
  • The formulation contains sorbitol, establishing a formal contraindication for individuals with hereditary fructose intolerance.
  • Co-administration is contraindicated in patients with a known serious hypersensitivity to the drug or its excipients.

Connection to the overall interaction profile (2–4 sentences):

The regulatory profile is characterized by the absence of systemic drug-drug interactions via metabolic pathways. Officially documented constraints are limited to mandatory administration separation due to intravenous compatibility and specific excipient-based prohibitions.

Mechanism of Action

Vyepti (eptinezumab-jjmr) is a humanized monoclonal antibody (IgG1) that functions as a highly selective antagonist targeting the Calcitonin Gene-Related Peptide (CGRP) ligand. CGRP is a naturally occurring neuropeptide centrally involved in the nociceptive signaling pathway of the trigeminal system. The biological target of eptinezumab-jjmr is the free circulating CGRP peptide itself, not its specific receptor.

The interaction is a high-affinity, stoichiometric binding event that physically sequesters CGRP molecules. By binding to and neutralizing CGRP, Vyepti prevents the neuropeptide from interacting with its cognate receptor (the CGRP receptor complex, CGRP-R). This mechanism classifies the drug as a CGRP ligand antagonist, which interrupts the downstream signaling process.

This molecular action leads to the modulation of neurovascular inflammation and vasodilation associated with the trigeminal pain system. By reducing the effective concentration of free, active CGRP, Vyepti modulates the entire mechanistic cascade of afferent sensory transmission within the nervous system.

Dosage and Administration Information

How Vyepti is Used: Official Administration Guidelines

Vyepti (eptinezumab-jjmr) is administered exclusively as an intravenous (IV) infusion in a healthcare setting, following a fixed schedule and strict preparation requirements.

Standard Dosing and Schedule

Administration Scope Official Instruction
Recommended Dose 100 mg administered every 3 months (or every 12 weeks).
Alternative Dose Some patients may benefit from a 300 mg dose administered every 3 months.
Missed Dose Rule If a dose is missed, administer Vyepti as soon as possible, and schedule subsequent doses every 3 months from the date of the last administered dose.

Required Administration Procedure

Due to its formulation as a concentrate, Vyepti must be diluted prior to infusion only in a 100 mL bag of 0.9% Sodium Chloride Injection. The diluted solution must be administered via IV infusion over approximately 30 minutes. The drug is explicitly not to be administered as an IV push or bolus injection. Official instructions also specify using a 0.2 micron or 0.22 micron sterile filter during the infusion process.

Use in Specific Populations

For older adults (65 years or older), the official label states no dose adjustment is required. Vyepti is not authorized for pediatric use (under 18 years of age). Dose adjustment is also not required for patients with renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Vyepti

Evidence for Use in Episodic Migraine Prevention

The clinical evaluation of Vyepti was studied for its role in the preventive treatment of adults experiencing episodic migraine. This condition is characterized by fluctuating or episodic manifestations, where symptoms may vary in intensity. The core evidence is derived from large, short-term Randomized Controlled Trials (RCTs). These trials are considered the highest standard of research and were used in research exploring how symptoms change over time compared to an inactive substance (placebo).

Researchers examined a variety of study findings related to physical discomfort, primarily tracking the change in the average number of Monthly Migraine Days (MMDs) from the beginning of the study. Research also monitored the proportion of subjects who reported a specific numerical reduction in MMDs over short time intervals (e.g., 12 weeks). These studies tracked the difference in MMD measurements between the Vyepti groups and the placebo groups. Findings describe patterns observed in the studies related to the time point at which changes in MMDs were first tracked, sometimes as early as the first day after the infusion.

Evidence for Use in Chronic Migraine Prevention

Vyepti was evaluated in multiple high-quality RCTs designed for adults with chronic migraine, a condition involving periods of heightened symptoms and marked by functional limitations. These studies explored populations that included those with Medication-Overuse Headache (MOH) and individuals who had previously documented failure of 2 to 4 prior preventive treatment classes.

The studies examined study findings related to physical discomfort (MMDs) and the use of acute medication. Data describe the patterns of MMD measurements that were tracked in the Vyepti groups compared to the placebo groups across these chronic migraine cohorts. Furthermore, trials applied in studies examining patient-reported experiences, tracking quality of life and subjects' functional status. This evidence contributes to the broader evidence landscape by providing insight into short-term changes for these specific groups.

Long-Term Research and Sustained Follow-up

Research has explored findings beyond the initial short-term trials through long-term, open-label extension studies that tracked subjects over defined time intervals extending up to two years. These studies monitored the maintenance of the previously measured MMD changes and patient-reported outcomes describing perceived discomfort.

However, the highest level of confidence—derived from double-blind, placebo-controlled evidence—follow-up durations were limited to shorter periods. The long-term observation periods contribute to understanding symptom patterns but are not fully established with the certainty provided by randomized, blinded research.

Research Gaps and Areas of Uncertainty

This body of evidence highlights what is known but also clarifies what is still uncertain.

  • Long-term effects are not fully established based on the highest-confidence evidence.
  • Comparative evidence is lacking from direct head-to-head randomized trials against other CGRP antagonists.
  • Data for certain groups remain insufficient, especially for the pediatric population (children and adolescents), where evidence is limited.
  • The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes. The study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Vyepti (FAQ)

Q: How quickly does Vyepti start working?

Studies show that some people may begin to see a benefit in reducing their migraine days as early as the day after receiving the intravenous infusion. This initial finding, tracked in clinical trials, indicates a quick onset of action.

Q: How long does the effect of Vyepti last?

Vyepti is designed to be administered as an intravenous infusion every three months (12 weeks) for migraine prevention. The long-acting nature of the medicine is supported by its half-life, which is approximately 27 to 28 days.

Q: Can Vyepti be used for chronic migraines only?

No, official regulatory documents state that Vyepti is indicated for the preventive treatment of migraine in adults, covering both those who experience episodic migraine and those who experience chronic migraine.

Q: Can Vyepti affect my blood pressure?

Reports collected after the drug became available (postmarketing data) have included new-onset or worsening of pre-existing hypertension (high blood pressure) following the use of CGRP-targeting medicines. Regulatory notes indicate the importance of monitoring for new or worsening high blood pressure, as this has been associated with CGRP-targeting medicines.

Q: Is Vyepti safe to use if I have heart problems?

Official product information notes that clinical studies generally excluded patients with a significant history of cardiovascular disease. For this reason, there are limited safety data available concerning the use of Vyepti in individuals with pre-existing heart problems.

Q: Is Vyepti safe for people over 65?

While clinical trials did not enroll enough patients aged 65 and over to fully assess differences in response, official labeling states that no change in dose is required for this older adult population.

Q: Does Vyepti interact with common over-the-counter pain relievers?

Formal drug-interaction studies involving specific over-the-counter pain relievers have not been conducted. However, systemic interactions with other medicines are considered unlikely because Vyepti is not metabolized by the major CYP enzyme system in the liver.

Q: Can Vyepti be taken with other migraine medications like triptans?

Official regulatory information indicates that formal studies for interactions with triptans or other specific migraine medicines have not been performed. Systemic pharmacokinetic interactions are deemed unlikely since the drug is not broken down by the major enzyme system responsible for drug metabolism (CYP450).

Q: Do I need to do anything special to prepare for a Vyepti treatment?

The medicine contains an inactive ingredient called sorbitol. Because of this, official prescribing information lists hereditary fructose intolerance (HFI) as an absolute contraindication, meaning the medicine must not be used by patients with this condition.

Q: Why is Vyepti given by IV infusion instead of a shot?

Vyepti is a large molecule, classified as a monoclonal antibody, which is uniquely formulated to be delivered via intravenous infusion over 30 minutes. This administration route is chosen to ensure the medicine has immediate and complete availability throughout the body.

Q: What is the difference between Vyepti and oral migraine preventatives?

Vyepti differs from oral preventive medicines primarily in its structure and delivery. It is a biological product (a monoclonal antibody) that is administered as an intravenous infusion every three months, a schedule that contrasts with the daily use of many oral treatments.

Q: What are the results of the main clinical trials for Vyepti?

The key finding from clinical trials demonstrated statistically significant reductions in the average number of Monthly Migraine Days (MMDs) when compared to an inactive substance (placebo). These results provide data used by regulators to describe the medicine's role in reducing the frequency of migraine attacks.

Q: How long do I have to use Vyepti before deciding if it works?

The primary clinical trials that established the medicine's effectiveness assessed the change in migraine frequency by tracking the average number of Monthly Migraine Days over the first three months (12 weeks) of treatment.

Q: What are the official warnings or precautions for Vyepti use?

The official product labeling includes warnings concerning the risk of serious Hypersensitivity Reactions, which can include anaphylaxis and angioedema. Other safety notes include the potential for new-onset or worsening of hypertension and Raynaud's phenomenon (a condition affecting blood flow to the extremities).

Q: Does Vyepti contain any preservatives or allergens?

The solution provided in the single-dose vial is formulated to contain no preservative. The medicine is formally contraindicated in patients with a known serious hypersensitivity to the drug or any of its inactive ingredients (excipients), or in those with hereditary fructose intolerance (HFI) due to the presence of sorbitol.

Q: How is Vyepti different from the other CGRP inhibitors?

Vyepti is distinct from other CGRP-targeting medicines because it is the only one administered as a 30-minute intravenous infusion in a healthcare setting. Other medicines in this class are typically administered as self-injected shots.

Q: Can Vyepti interact with birth control pills?

Official regulatory information indicates that formal studies for interactions with birth control pills or other specific hormonal medications have not been performed. However, systemic interactions are deemed unlikely since the drug is not broken down by the major enzyme system responsible for drug metabolism (CYP450).

Q: Can Vyepti cause problems with the liver or kidneys?

Official guidelines state that no adjustment to the dose is required for patients with either existing kidney impairment (renal impairment) or liver impairment (hepatic impairment).

Q: Is Vyepti considered a long-term treatment?

The clinical evidence supporting Vyepti includes long-term, open-label extension studies where subjects continued treatment for up to two years. These studies contribute to understanding the safety and effect of the medicine over an extended period.

Q: Do studies suggest Vyepti reduces headache severity?

While the main measure of effectiveness in clinical trials was the reduction in Monthly Migraine Days (MMDs), long-term studies also tracked and suggested sustained reductions in headache frequency and pain severity over time.

Q: What is the meaning of the study endpoints used for Vyepti trials?

The effectiveness of Vyepti was measured using key study endpoints, primarily tracking the change in the average number of Monthly Migraine Days (MMDs) from the start of the study. Researchers also measured the percentage of subjects who experienced a significant reduction (e.g., 50% or more) in their MMDs.

Q: Is weight gain a side effect of Vyepti?

Based on the data collected during the clinical trials, weight gain was not reported as an adverse reaction.

Q: Is Vyepti the same as Aimovig, Ajovy, or Emgality?

No, Vyepti is a distinct medicine from Aimovig, Ajovy, and Emgality. While they all belong to the class of CGRP-targeting drugs, Vyepti is a different chemical entity and is uniquely administered as an intravenous infusion, whereas the others are subcutaneous injections.

Q: Can Vyepti be used for tension headaches or cluster headaches?

Vyepti is only officially indicated for the preventive treatment of migraine in adults. The official regulatory documents do not include an indication for the use of the medicine for tension headaches or cluster headaches.

Q: Can Vyepti cause dry mouth or constipation?

Dry mouth and constipation are not listed among the common adverse reactions reported in the official product information based on the clinical trials.

Q: Is there a generic version of Vyepti available?

Vyepti (eptinezumab-jjmr) is a biological product. As of the current regulatory approvals, there is no generic or biosimilar version of this medicine available.

Q: Can Vyepti cause anxiety or mood changes?

Anxiety or general mood changes are not listed as common adverse reactions in the official regulatory documents. However, safety surveillance in clinical trials specifically included monitoring for events such as suicidal ideation and behavior.

Q: Is Vyepti an opioid or a controlled substance?

Vyepti is classified as a Calcitonin Gene-Related Peptide (CGRP) Antagonist. It is not classified as an opioid medicine or a controlled substance by regulatory authorities.

Q: Does Vyepti have a risk of drug dependence?

Official regulatory documents state that, as a biological product used for prevention, Vyepti is not associated with a risk of drug dependence.

Q: Are there any specific foods or drinks to avoid while on Vyepti?

Official regulatory information focuses on intravenous compatibility, requiring that no other medicines be mixed with the infusion solution. There are no specific warnings or required restrictions regarding foods or drinks to avoid while using Vyepti.

Q: Does Vyepti work better for certain types of migraines?

Clinical trials tracked and reported the effectiveness of Vyepti separately for patients with episodic migraine and those with chronic migraine. This information is available in the research evidence reviewed by regulatory bodies.

How should Vyepti be stored and disposed of?

How to Store and Dispose of Vyepti

Vyepti (eptinezumab-jjmr) is a biological product that requires strict adherence to documented storage and disposal rules to maintain its quality and safety, as outlined in regulatory information.

Storage Requirements

Condition Requirement (Unopened Vial)
Temperature Store refrigerated between 2 C and 8 C (36 F to 46 F).
Protection Keep in the original carton to protect the solution from light.
Prohibited Do not freeze and do not shake the vial.
Child Safety Keep out of the sight and reach of children.

The solution for infusion must be administered within 8 hours of dilution. The single-dose vial contains no preservative, and the solution must be visually inspected for discoloration or particles before preparation.

Disposal

Any unused portion remaining in the single-dose vial must be discarded. To protect the environment, the medicine must not be disposed of via wastewater or household waste; disposal must follow local guidelines established by a healthcare professional or pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vyepti found in:

A-Z Index: